Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 03:57 PM ET
After-Market: $236.32 -0.02 (-0.01%) 5:34 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 03:57 PM ET
After-Market: $236.32 -0.02 (-0.01%) 5:34 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Becton Dickinson (BDX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
BD (BDX) Collaborates With Hamilton to Benefit Researchers
by Zacks Equity Research
Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.
Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GameStop and Becton, Dickinson and Company have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
GameStop and Becton, Dickinson and Company are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Becton, Dickenson and Co (BDX)
by David Bartosiak
Earnings have been retreating on this Bear of the Day.
New Strong Sell Stocks for December 11th
by Zacks Equity Research
DG, BDX and CIGI have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2023.
BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod
by Zacks Equity Research
BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.
BD (BDX) Launches Advanced Vascular Access Management System
by Zacks Equity Research
BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.
BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.
Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Unlocking Q4 Potential of Becton Dickinson (BDX): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 2.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 8.43% and 1.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk
by Zacks Equity Research
Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.
Top Stock Reports for Apple, Amgen & Becton, Dickinson
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes
by Zacks Equity Research
BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.
AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.
DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.42% and 1%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for BD (BDX) This Earnings Season?
by Zacks Equity Research
BD (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.